We have found that treatment of NSCLC cells with honokiol enhances the expressions of CK1α and GSK-3β as well as enhanced phosphorylation of β-catenin at critical serine and threonine target residues. The gene discussed is CSNK1A1; the disease is non-small cell lung carcinoma.